MarketPeel
Insider Trading Intelligence
JL

Jason A. Leverone

OKUR
CHIEF FINANCIAL OFFICER · ONKURE THERAPEUTICS, INC. · CIK 0001692747
FILING MIX · LIFETIME50%/50%
BUYS
7
SELLS
7
TOTAL VALUE
$14.2K
COMPANIES
2
ACTIVE SINCE
Jan 2021
HOLDINGS NOW
330,587
AVG SELL PX
$3.06
TRADE KIND
SHOWING 14 / 14
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 10 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Jason A. Leverone, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+83.33%-3.30%+1.98%-5.28%-6.14%
14d6+66.67%-0.97%+1.86%-2.83%-3.86%
30d6+66.67%-2.95%+6.20%-9.15%-5.19%
60d6+66.67%-2.41%+8.76%-12.11%-12.83%
90d6+33.33%+3.69%+11.71%-8.03%-2.10%
180d6(1 pending)+40.00%+21.96%+16.93%+5.02%+11.49%
1y6(3 pending)+0.00%+53.93%+28.18%+25.75%+8.14%
2y6(6 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
OKUR · 18,802 shares · as of Jun 22, 2026
032,65365,30697,958130,61120252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 7 buys / 7 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
OKUR
ONKURE THERAPEUTICS, INC.
SALE
Chief Financial Officer
303$4.40$1.3K18,802Jun 22, 2026Jun 24, 2026View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
110,000110,000Apr 1, 2026Apr 3, 2026View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
Chief Financial Officer
301$4.16$1.3K16,000Mar 23, 2026Mar 24, 2026View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
Chief Financial Officer
302$2.97$89616,301Dec 22, 2025Dec 23, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
Chief Financial Officer
303$2.62$79512,603Sep 22, 2025Sep 24, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
Chief Financial Officer
303$2.38$72212,906Jun 23, 2025Jun 25, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,844$2.67$4.9K13,209Apr 7, 2025Apr 8, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,278$3.33$4.3K15,053Apr 4, 2025Apr 8, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
65,00065,000Jan 27, 2025Jan 29, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
16,33116,331Oct 4, 2024Oct 8, 2024View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,7815,781Oct 4, 2024Oct 8, 2024View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,3225,322Oct 4, 2024Oct 8, 2024View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
130,611130,611Oct 4, 2024Oct 8, 2024View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASEGRANT
Stock grant
311,785311,785Jan 18, 2021Jan 20, 2021View →
Other insiders · OKUR
Loading peer insiders…
About this filer
CIK 0001692747
ROLE
Chief Financial Officer
PRIMARY
OKUR
COMPANIES
2
ACTIVE SINCE
Jan 2021
MARKETPEEL · /INSIDER/0001692747DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback